Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Belite Bio, IncNASDAQ: BLTE
EPS (Basic) · Q3 FY2026 · quarter ended Sep 2026
EPS (Basic) remains negative
Q3 FY2026 EPS (Basic) was -$0.75, compared with -$0.65 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.86.
Context
- EPS (Basic) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -$3.3 (-42.8%) for the fiscal year ending Dec 2026, a step up from the -95.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.75-5.6% QoQ
- Last fiscal yearDec 2025
- -$2.31-95.8% YoY
- LTMSep 2026
- -$2.86-49.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.4% | -32.3% | -17.0 pp |
| 1 year | -95.8% | -42.8% | +53.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (2.31) USD
- Year-over-year change
- -95.8%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.31) | -95.8% |
| FY2024 | 2024-12-31 | (1.18) | +0.8% |
| FY2023 | 2023-12-31 | (1.19) | -88.9% |
| FY2022 | 2022-12-31 | (0.63) | -57.5% |
| FY2021 | 2021-12-31 | (0.40) | — |
EPS (Basic) vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Sep 2026 EPS (Basic) of -$2.86 is the 4th highest of the 6 companies compared; the peer median is -$2.15.
- Its year-over-year change of -49.7% is the lowest of 6, against a peer median of +1.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.23 | -24.7% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$1.31 | +32.5% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$2.15 | +85.6% | — |
BLTEBelite Bio, Inc | LTM Sep 2026 | -$2.86 | -49.7% | — |
| LTM Mar 2026 | -$3.5 | -45.2% | — | |
| LTM Sep 2026 | -$4.08 | +1.0% | — | |
| Peer median (excluding BLTE) | -$2.15 | +1.0% | — | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.